Integrating Tumor Microenvironment into Cancer Therapy Development
July 24, 2025
The evolution of cancer treatment has been significantly advanced by immunotherapies and molecularly targeted agents, yet many patients still lack lasting responses. The genetic model of cancer has enhanced our understanding of the disease but often oversimplifies it as merely cell-autonomous mutations. It has overlooked the complexity of solid tumors as disease tissues, where the tumor microenvironment (TME) plays a critical role. The TME, a dynamic ecosystem of cells, impacts cancer etiology and treatment outcomes, making its consideration crucial in therapeutic design.
Historically, cancer models focused primarily on genetics, neglecting the TME’s complexity. Many preclinical models lack the stromal components characteristic of human tumors, leading to treatments tested without accounting for the TME’s influence. Cancer-associated fibroblasts (CAFs) within the TME shape the tumor landscape, impacting drug delivery and immune response. Their heterogeneity and plasticity pose challenges in developing effective therapies.
Current strategies often aim to co-target the stroma and tumors, emphasizing the TME’s dynamic nature. For example, stromal therapies’ impact varies across cancer types and conditions, highlighting the need for careful design. Incorporating TME considerations into drug development and clinical trials can enhance therapeutic efficacy, particularly in immune-resistant tumors.
To advance cancer treatment, we must integrate TME analysis into drug development, improve preclinical models, and foster interdisciplinary collaboration. This approach parallels immunotherapy’s development, where detailed functional understanding led to transformative treatments. Understanding and manipulating the TME can revolutionize cancer therapy by overcoming resistance and maximizing therapeutic potential.
To read more, click here.
[Source: PLOS Biology, July 24, 2025]